

Supplemental information

**IFP35 as a promising biomarker
and therapeutic target for the syndromes induced
by SARS-CoV-2 or influenza virus**

Yang Yu, Na Xu, Qi Cheng, Fei Deng, Meiqin Liu, Airu Zhu, Yuan-Qin Min, Dan Zhu, Wenbo Huang, Xu Feng, Xizhong Jing, Ying Chen, Daoyuan Yue, Yawei Fan, Chang Shu, Qing Guan, Zifeng Yang, Jincun Zhao, Wenjun Song, Deyin Guo, Huanliang Liu, Jindong Zhao, Ping Lan, Zhengli Shi, Yingfang Liu, Xiaoping Chen, and Huanhuan Liang

SUPPLEMENTARY MATERIALS

Table S1. The information of 112 laboratory confirmed COVID-19 patients in Group 1. Related to Figure 1.

Patients	Gender	Age (years)	Patient's condition on admission	Patient's turnover	LDH (135-214 U/L)	D-dimer < 0.5 µg/ml	Blood cell count ($\times 10^9/L$)			Serum Conc. (pg/ml)				CRP (µg/ml)
							Platelet	Lymphocyte	Neutrophil	IFP35	IL-6	TNF	PCT	
							125-350	1.10-3.20	1.80-6.30					
3.83	F	57	mild	improve	179	0.26	274	1.78	3.25	ND	1.5	5.8	NA	0.9
3.84	M	40	mild	improve	184	0.29	280	1.79	5.48	31.7	1.73	8.7	NA	2.9
3.85	F	56	mild	improve	187	< 0.22	217	2.44	3.60	ND	1.54	5.9	NA	1.2
3.87	M	60	mild	improve	160	0.35	273	3.13	3.88	38.86	3	6.8	NA	0.7
22	F	63	ordinary	improve	187	0.38	243	1.63	2.59	ND	4.32	4	20	0.3
27	F	71	ordinary	improve	255	0.52	137	0.89	2.15	ND	12.49	6.2	20	1
32	M	38	ordinary	improve	206	0.21	257	2.97	5.85	ND	3.61	6.1	30	21.4
33	F	61	ordinary	improve	182	0.45	149	1.06	3.31	ND	5.69	10.3	50	3.9
39	M	71	ordinary	improve	228	8.34	157	1.00	2.12	ND	37.56	9.5	40	78.2
57	F	63	ordinary	improve	241	0.23	335	2.35	2.56	ND	1.5	5.4	20	0.8
65	F	65	ordinary	improve	250	0.21	160	1.48	3.54	ND	3.99	9.3	70	1.6
76	F	31	ordinary	improve	181	1.34	370	1.50	3.06	ND	3.63	5.6	30	0.5
78	F	68	ordinary	improve	238	0.43	217	1.15	3.06	ND	22.11	6.3	20	23.4
97	M	48	ordinary	improve	242	0.56	237	1.04	3.37	481.24	8.11	7.5	30	4.1
98	F	70	ordinary	improve	221	0.23	251	0.93	2.49	67.82	2.76	4	40	2.1
99	F	70	ordinary	improve	169	2.37	232	0.78	4.98	159.47	1.5	5.9	60	1.4
102	M	30	ordinary	improve	207	1.01	233	2.20	3.80	13.32	1.83	4.7	60	1.1
1.1	M	42	ordinary	improve	209	0.36	295	1.10	1.56	ND	150.4	19.18	20	0.6
1.3	F	45	ordinary	improve	220	0.84	425	1.63	2.88	83.88	27.62	5.21	20	0.6

1.4	F	61	ordinary	improve	284	0.63	181	1.05	3.40	47.75	28.45	3.66	40	88.5
1.14	F	48	ordinary	improve	287	0.38	385	1.56	2.82	431.84	5.04	11.42	20	2.0
1.18	F	75	ordinary	improve	217	0.58	327	1.24	3.99	51.77	3.87	4.05	30	12.0
1.19	F	35	ordinary	improve	341	0.34	242	1.41	1.21	533.42	6.36	3.66	20	58.9
1.23	M	59	ordinary	improve	206	< 0.22	115	2.75	3.40	124.02	6.03	23.06	20	1.7
1.25	M	65	ordinary	improve	371	0.43	341	1.54	3.66	107.96	4.87	4.44	20	3.5
1.90	F	61	ordinary	improve	300	0.25	582	1.49	4.79	501.31	0.55	9.87	50	1.6
1.91	F	63	ordinary	improve	187	2.28	176	1.40	2.56	ND	51.71	5.99	60	19
1.93	M	75	ordinary	improve	209	0.85	335	1.82	4.82	1143	3.87	4.05	50	15.7
1.95	F	76	ordinary	improve	225	0.43	264	1.61	3.34	1139.51	8.36	24.61	50	2.5
8	M	60	severe	improve	313	1.53	276	0.67	7.83	536.70	304.7	10.6	160	175.9
11	M	69	severe	improve	292	2.63	181	0.75	2.95	156.14	12.66	7.6	50	75.1
12	M	67	severe	improve	704	3.16	263	0.67	4.14	374.53	296.9	13.7	660	135
26	M	76	severe	improve	399	1.49	168	0.70	5.63	448.05	155	11.8	120	192.4
34	F	80	severe	improve	177	0.75	115	1.85	2.95	450.61	4.32	7.9	50	2.3
35	M	82	severe	improve	208	1.10	247	2.01	4.04	797.28	7.35	9.2	30	6.2
36	M	73	severe	aggravation	246	0.40	329	1.73	3.53	588.02	15.86	9	40	40.6
38	M	66	severe	improve	249	0.35	345	1.23	3.85	ND	3.13	5.2	20	1.5
40	F	63	severe	improve	391	> 21	378	2.08	6.53	273.33	5.84	4	20	3.9
41	F	69	severe	improve	226	0.29	375	1.52	5.92	96.05	5.09	7.4	50	3.8
42	F	72	severe	improve	258	0.48	488	1.84	3.55	190.60	3.77	6.6	20	4.1
43	M	37	severe	improve	351	0.22	460	2.33	5.22	1092.75	4.03	14.9	60	5.2
46	M	64	severe	improve	452	0.80	320	0.71	3.83	248.40	67.21	9.2	60	46.2
47	F	74	severe	improve	307	9.76	168	1.69	2.15	629.75	22.63	8.3	40	27.2
51	F	38	severe	improve	243	1.47	342	1.47	7.41	769.71	5.31	4.3	20	1.9

52	M	74	severe	improve	284	0.64	209	0.68	2.80	ND	15.63	8.3	50	32.5
53	F	69	severe	improve	350	0.48	217	0.78	3.41	88.17	103.7	13	370	81.8
54	M	57	severe	aggravation	339	2.12	319	0.49 ↓	6.23	458.49	57.4	7.1	50	114.7
55	M	72	severe	improve	267	0.87	363	0.97	7.00	ND	53.35	13.1	110	175.8
56	F	86	severe	improve	368	1.05	238	0.80	3.54	328.48	39.99	13.1	130	131.1
58	F	69	severe	improve	271	2.57	240	0.52	2.55	261.78	16.51	4.4	20	25.7
59	M	65	severe	improve	272	1.53	212	0.81	4.29	ND	43.7	12.2	170	121.9
60	M	82	severe	improve	326	2.54	109	0.77	5.34	880.01	58.74	9	190	77.6
61	F	46	severe	improve	288	1.22	417	1.51	6.90	403.33	1.93	8.7	30	8.0
62	F	64	severe	improve	266	0.51	172	0.73	3.76	ND	35.08	5.8	50	88.2
63	M	70	severe	improve	777	> 21	359	0.77	11.94	40.90	99.64	NA	160	162.6
64	M	78	severe	aggravation	479	1.83	211	0.64	6.20	139.39	119.6	15.9	70	42.6
67	M	82	severe	improve	218	0.75	285	1.15	5.22	ND	28.38	16.2	70	35.3
68	F	58	severe	improve	263	0.53	309	1.40	2.07	155.15	1.65	5.9	20	1.0
70	F	46	severe	improve	248	0.24	453	1.55	5.54	686.98	3.53	5.3	20	2.0
71	M	80	severe	improve	192	2.36	129	1.30	5.10	344.24	17.41	8.5	40	6.4
72	F	58	severe	improve	346	0.83	408	0.94	11.53	ND	31.14	9.8	30	80.7
75	M	75	severe	improve	325	1.39	259	0.87	4.92	ND	9.54	8.3	20	4.9
100	F	67	severe	aggravation	190	1.14	275	0.85	3.23	3287.19	20.77	8.7	60	25.9
1.2	F	58	severe	improve	202	0.23	247	1.44	2.36	637.78	3.54	7.54	20	0.8
1.7	F	70	severe	improve	315	1.89	285	0.90	6.49	4298.37	13.17	16.08	80	9.9
1.9	M	77	severe	aggravation	248	2.67	295	1.62	8.94	172.32	37.92	19.57	90	23.5
1.10	M	65	severe	improve	568	2.75	306	0.97	6.79	1713.48	3.54	19.18	450	91.6
1.15	F	61	severe	improve	274	0.48	223	0.74	2.98	388.93	39.58	23.83	30	13.1
1.17	F	71	severe	improve	424	4.68	279	0.68	7.66	1099.37	68.65	7.15	330	258.0

1.20	M	28	severe	improve	258	0.44	533	1.63	7.39	2431.95	4.87	12.58	NA	1.2
1.24	M	77	severe	improve	267	2.75	330	0.68	5.77	2235.27	220.3	26.94	50	146.3
1.28	M	70	severe	improve	268	2.67	383	2.05	6.31	1637.22	7.69	0.95	50	5.9
1.30	F	80	severe	improve	198	0.52	250	0.61	5.77	509.34	9.69	6.38	30	5.0
1.31	M	72	severe	improve	313	9.73	173	0.92	4.21	1524.83	27.46	8.32	70	58.4
1.37	M	56	severe	improve	314	1.31	129	0.55	2.10	1103.38	17.66	9.48	50	68.3
1.45	M	51	severe	improve	506	1.27	239	0.83	4.34	1171.62	68.11	16.08	210	99.6
1.49	F	64	severe	improve	222	0.37	258	1.62	2.22	557.51	1.59	4.05	30	2.7
1.50	F	66	severe	improve	291	0.77	327	1.39	5.47	3383.22	8.13	4.05	20	6.2
1.69	M	60	severe	aggravation	681	11.07	391	1.14	11.66	207.66	86.25	5.60	460	217.5
1.73	F	66	severe	improve	290	1.10	277	1.01	2.18	1019.09	11.68	16.85	120	42.7
1.74	F	63	severe	improve	237	0.42	131	0.50 ↓	1.70	778.26	27.96	7.15	30	22
1.77	M	50	severe	aggravation	414	1.79	177	0.92	5.11	736.27	86.25	10.64	540	68.2
1.79	F	76	severe	improve	497	5.21	223	0.85	5.61	2520.25	69.31	30.04	80	104.4
1.80	M	38	severe	improve	360	0.65	211	0.92	3.36	593.63	18.99	12.20	100	63.5
1.81	F	76	severe	improve	418	> 60	193	0.43	7.09	593.63	12.18	11.03	710	118.4
1.82	F	55	severe	improve	220	0.23	194	1.01	3.47	738.13	31.61	3.27	40	25.6
1.83	F	69	severe	improve	193	0.38	207	1.67	2.75	561.52	10.68	6.77	50	18.4
1.84	F	59	severe	improve	243	0.27	404	1.60	2.99	509.34	5.70	12.20	60	10.9
1.85	F	69	severe	improve	199	0.38	276	1.36	2.32	481.24	1.88	8.32	50	2.1
1.86	M	79	severe	improve	269	0.78	165	0.21	3.37	1063.24	70.97	14.91	90	72.3
1.87	F	61	severe	improve	247	0.49	429	0.52	6.36	3993.32	6.36	18.79	40	10.5
1.88	M	65	severe	improve	308	0.72	282	0.83	10.03	6257.1	9.35	18.01	80	15.8
1.89	F	69	severe	improve	199	0.38	276	1.36	2.32	2078.74	1.55	8.32	50	2.1
1.92	M	69	severe	improve	246	0.79	335	0.98	3.69	1059.23	14.17	7.15	50	31.2

1.94	M	67	severe	improve	260	1.67	230	0.82	3.51	3013.95	9.69	9.87	50	17.6
1.96	F	60	severe	improve	320	0.60	330	1.34	1.84	898.68	6.03	4.83	70	14.0
1.101	F	76	severe	improve	320	1.95	237	0.52	9.91	1225.14	49.92	7.3	850	185.9
1.112	F	60	severe	aggravation	622	> 21	622	0.58	18.87	493.46	268	10.2	NA	NA
1.16	F	60	severe	death	1549	> 21	146	0.64 ↓	16.00	5141.27	179.1	31.20	670	270.6
1.21	F	87	severe	death	325	1.23	145	0.73 ↓	1.77	493.28	29.45	11.42	100	75.5
13	M	73	critical	death	1772	> 21	42	0.44 ↓	8.59	2144.59	111.7	22.8	940	274.1
44	F	82	critical	death	664	> 21	131	0.64 ↓	15.44	186.66	207.7	13.3	870	293.4
106	M	75	critical	death	370	19.34	64	0.69 ↓	10.13	3709.16	322.1	12.6	140	174.7
109	M	70	critical	death	721	> 21	31	0.12 ↓	10.29	214.74	249.2	8.2	130	69
110	M	71	critical	death	489	4.27	141	0.23 ↓	5.98	451.62	232.5	25.4	890	147
48	M	86	critical	aggravation	480	1.49	259	0.33 ↓	5.47	103.93	64.88	17.3	450	189.7
103	F	60	critical	aggravation	622	> 21	55	0.58 ↓	18.87	74.20	268	6.2	660	104.8
104	F	67	critical	aggravation	813	8.96	275	0.29 ↓	12.66	31.56	258.4	9.7	110	142.7
105	M	84	critical	aggravation	464	13.52	54	0.32 ↓	7.58	151.05	210	18.9	360	120.9
107	M	58	critical	aggravation	736	1.78	173	0.35 ↓	7.32	169.47	198	11.8	100	18.7
111	F	80	critical	aggravation	362	2.88	84	0.53 ↓	12.10	73.14	103.1	14.5	230	145.2
1.29	F	58	critical	aggravation	310	1.77	181	0.67 ↓	3.34	501.84	81.77	0.95	3530	150.8

The patients were blooded on admission. Their sera were isolated and used for laboratory detection. “ND” meant the concentration was not detectable. “NA” meant the data was not available. For statistical comparisons, undetectable data (ND) were defined as “0”. LDH is the abbreviation of lactate dehydrogenase. Lymphocyte count less than $1.10 \times 10^9/L$ was highlighted using “↓”.

Table S2. The information of 38 laboratory confirmed COVID-19 patients in Group 2. Related to Figure 3.

Patients	Gender	Age (years)	Patient's condition on admission	Patient's turnover	Days of treatment	LDH (135-214 U/L)	D-dimer < 0.5 µg/ml	Blood cell count ($\times 10^9/L$)			Serum Conc. (pg/ml)				CRP (µg/ml)
								Platelet	Lymphocyte	Neutrophil	IFP35	IL-6	TNF	PCT	
								125-350	1.10-3.20	1.80-6.30					
2.20	F	48	mild	improve	6	198	0.21	159	1.30	2.37	34.88	1.5	4.3	20	0.4
2.28	M	54	mild	improve	19	195	< 0.22	146	1.76	2.83	32.89	1.5	5.2	20	1.8
2.29	F	51	mild	improve	5	234	2.49	188	2.13	2.20	42.84	1.98	4.6	20	0.3
2.30	F	35	mild	improve	19	140	1.04	219	1.56	2.95	ND	1.5	4	20	0.3
2.34	F	45	mild	improve	5	154	< 0.22	140	1.40	2.77	ND	1.5	4.6	20	0.6
2.12	F	70	severe	improve	21	222	1.05	349	2.10	2.63	34.33	1.5	9.1	30	2.2
2.14	F	57	severe	improve	21	293	0.70	167	1.61	1.97	269.74	1.73	5.1	30	0.3
2.15	F	78	severe	improve	21	149	0.39	206	1.14	3.36	122.45	3.4	6.2	30	1.5
2.37	F	84	severe	improve	19	223	1.53	256	0.76	8.32	ND	20.7	10.4	40	12.9
2.41	M	44	severe	improve	21	194	0.32	aggregation	1.27	1.99	22.80	7.1	1.5	70	2.6
3.12	M	56	severe	improve	22	259	2.54	422	1.37	7.87	632.00	12.15	6	110	47.4
3.90	M	42	severe	improve	27	387	2.17	173	1.48	11.64	192.90	8	18.4	200	29.9
2.11	F	81	critical	improve	19	160	0.23	129	0.50 ↓	2.05	48.03	6.75	6.6	40	0.5
2.25	F	46	critical	improve	8	179	2.12	130	0.20 ↓	4.33	126.44	8.5	31.2	300	24.1
2.27	M	69	critical	improve	22	231	2.47	312	1.33	4.81	158.28	5.72	13.9	80	4.1
2.31	M	46	critical	improve	10	265	2.82	94	1.30	7.83	ND	19.62	4.8	20	19.3
2.32	M	54	critical	improve	21	309	9.22	315	1.12	4.37	14.97	3.3	4	40	12.7
3.13	F	55	critical	improve	31	300	2.56	522	1.62	7.57	ND	9.61	9.8	40	69.3
3.14	F	73	critical	improve	22	236	5.27	208	1.61	3.65	695.69	9.02	4	140	5.9
3.57	M	66	critical	improve	24	210	< 0.22	239	1.84	3.05	154.30	2.37	8.3	40	0.8

3.59	M	47	critical	improve	23	136	1.89	364	0.78	3.15	ND	4.65	6.7	180	5.2
3.60	M	89	critical	improve	23	327	1.08	149	2.61	2.33	ND	2.27	6.5	30	1.8
3.62	M	81	critical	improve	24	163	2.90	195	1.59	3.92	249.84	6.2	15.1	80	4.6
3.63	M	72	critical	improve	24	186	0.72	257	0.74	4.08	ND	91.01	10.8	90	17.3
3.81	F	65	critical	improve	17	213	3.71	296	1.12	4.75	600.15	30.62	8.5	60	30.5
3.91	M	56	severe	aggravation	27	784	2.98	73	0.71	13.04	458.14	65.63	13	1430	82.1
3.88	M	69	critical	aggravation	17	271	11.80	99	1.63	14.79	198.67	25.2	236.	2.44	212.6
3.10	F	63	severe	death	26	284	1.78	83	0.28 ↓	4.17	2853	15.7	136	1260	74.8
2.18	F	68	severe	death	20	456	15.01	186	0.48 ↓	17.6	2726	37.14	11.5	2680	42.1
3.64	F	57	severe	death	27	1052	1.01	24	2.00	30.20	1704.4	675.8	22.4	1940	298.2
3.1	M	71	severe	death	32	612	2.07	16	0.43 ↓	17.64	5938.4	121.7	8.7	1140	67.7
3.4	M	68	severe	death	26	742	1.81	32	0.55 ↓	14.26	9545	72.37	20.4	25130	112.3
2.24	M	78	critical	death	6	338	4.73	81	0.11 ↓	11.63	1046	27.43	9.1	620	47
2.40	M	67	critical	death	4	354	5.17	58	0.81 ↓	21.16	3553.9	2308	19.6	2080	159.5
3.2	F	68	critical	death	31	402	0.33	275	0.75 ↓	9.50	1227.3	8.07	4.6	40	17.6
3.61	M	65	critical	death	31	346	5.42	43	1.43	13.67	12435	5000	38.2	24840	300
3.86	M	66	critical	death	34	248	3.83	49	1.20	26.45	9644.5	61.5	5000	10020	221.8
3.89	M	51	critical	death	27	440	3.82	166	0.20 ↓	22.47	839	7.7	31	570	151.7

The patients were blooded after the treatment. Their sera were isolated and used for laboratory detection. “ND” meant the concentration was not detectable. “NA” meant the data was not available. For statistical comparisons, undetectable data (ND) were defined as “0”. LDH is the abbreviation of lactate dehydrogenase. Lymphocyte count less than $1.10 \times 10^9/L$ was highlighted using “↓”.

Table S3. The information of 8 laboratory confirmed COVID-19 patients in Group 3. Related to Figure 3.

Patients	Gender	Age (years)	Patient's condition on admission	Patient's turnover	Blood date	LDH (135-214 U/L)	D-dimer < 0.5 µg/ml	Blood cell count ($\times 10^9/L$)			Serum Conc. (pg/ml)				CRP (µg/ml)
								Platelet	Lymphocyte	Neutrophil	IFP35	IL-6	TNF	PCT	
								125-350	1.10-3.20	1.80-6.30					
2501787353	M	60	severe	improve	2/10/2020	313	1.53	276	0.67	7.83	536.70	304.7	10.6	160	175.9
					3/1/2020	258	1.65	451	1.26	63.5	ND	6.95	11.7	90	7.8
2501798952	M	69	severe	improve	2/10/2020	292	2.63	181	0.75	2.95	156.14	12.66	7.6	50	75.1
					3/5/2020	166	0.47	161	1.68	3.82	74.68	4.04	6.1	NA	2.8
2501787356	M	67	severe	improve	2/10/2020	704	3.16	263	0.67	4.14	374.53	296.9	13.7	660	135
					3/2/2020	243	1.86	237	2.45	2.20	63.16	4.54	7.1	50	1.1
2501787359	M	76	severe	improve	2/10/2020	399	1.49	168	0.70	5.63	448.05	155	11.8	120	192.4
					3/2/2020	182	0.63	220	1.51	3.08	150.32	2.14	8.1	0.04	1.4
2501787142	M	64	severe	improve	2/10/2020	452	0.80	320	0.71	3.83	248.40	67.21	9.2	60	46.2
					3/1/2020	267	0.22	243	1.33	2.22	ND	1.5	6.1	20	0.5
2501798951	F	69	severe	improve	2/10/2020	350	0.48	217	0.78	3.41	88.17	103.7	13	370	81.8
					3/5/2020	178	1.21	286	1.37	1.95	ND	2.61	10	NA	0.7
2501787345	F	86	severe	improve	2/10/2020	368	1.05	238	0.80	3.54	328.48	39.99	13.1	130	131.1
					3/1/2020	171	1.43	269	1.09	2.18	18.95	2.1	10.9	50	6.2
2501787347	F	69	severe	improve	2/10/2020	271	2.57	240	0.52	2.55	261.78	16.51	4.4	20	25.7
					3/1/2020	250	0.21	160	1.48	3.54	ND	1.59	4	80	3.1

The patients were blooded both before and after the treatment. Their sera were isolated and used for laboratory detection. “ND” meant the concentration was not detectable. “NA” meant the data was not available. For statistical comparisons, undetectable data (ND) were defined as “0”. LDH is the abbreviation of lactate dehydrogenase.

Table S4. The information of uninfected people. Related to Figure 1.

uninfected people	Gender	Age	Serum Conc. (pg/ml)
			IFP35
001	F	25 years	286.085
002	F	30 years	ND
003	F	27 years	ND
004	F	29 years	117.6524*
005	F	27 years	87.929*
006	F	27 years	28.4822*
007	F	28 years	ND
008	F	32 years	127.5602*
009	F	28 years	276.1772
010	F	27 years	241.4999
011	F	70 years	ND
012	F	79 years	ND
013	F	71 years	ND
014	F	63 years	ND
015	F	62 years	ND
016	F	62 years	ND
017	F	62 years	ND
018	F	62 years	ND
019	F	63 years	ND
020	F	63 years	ND
021	M	31 years	276.1772

022	M	29 years	395.0708
023	M	33 years	ND
024	M	25 years	ND
025	M	33 years	ND
026	M	29 years	ND
027	M	32 years	ND
028	M	33 years	ND
029	M	24 years	ND
030	M	27 years	ND
031	M	62 years	ND
032	M	60 years	ND
033	M	60 years	ND
034	M	71 years	ND
035	M	63 years	ND
036	M	73 years	ND
037	M	66 years	ND
038	M	80 years	ND
039	M	79 years	ND
040	M	67 years	ND

“ND” meant the value was not detectable. “NA” meant the data was not available. For statistical comparisons, undetectable data (ND) were defined as “0”. “*” meant the data was below the limit of detection.

Table S5. Clinical characteristics and laboratory detection of 112 confirmed COVID-19 patients of Group 1. Related to Figure 1.

Characterization	All patients N = 112	Not-severely-ill N = 29	Severely-ill N = 83
Age - median year (range)	64 (31-87)	58 (31-76)	67 (37-87)
Patient's turnover (No.)	Improve (90)	Improve (29)	Improve (61)
	Aggragation (15)		Aggravation (15)
	Death (7)		Death (7)
Gender	No. (%)		
Male	51 (46%)	10 (34%)	41 (49%)
Female	61 (54%)	19 (66%)	42 (51%)
Blood cell count	No. (%)		
Neutrophil	No. (%)		
≥ 6.3×10 ⁹ /L	29 (25%)	0 (0)	29 (35%)
1.8-6.3×10 ⁹ /L	80 (71%)	27 (93%)	52 (63%)
≤ 1.8×10 ⁹ /L	4 (4%)	2 (7%)	2 (2%)
Lymphocyte count	No. (%)		
< 1.1×10 ⁹ /L	63 (56%)	7 (24%)	56 (67%)
Mean ± SD	1.24 ± 0.68	1.61 ± 0.62	1.08 ± 0.60
Platelet count	No. (%)		
< 125×10 ⁹ /L	9 (8%)	1 (3%)	8 (10%)
Distribution of other findings	No. (%)		
CRP (≥ 10 µg/mL)	68 (60%)	8 (28%)	60 (72%)
Lactose dehydrogenase (≥ 250 U/L)	68 (60%)	7 (24%)	61 (73%)

Procalcitonin (≥ 0.05 ng/mL)	67 (59%)	8 (28%)	59 (71%)
D-dimer (≥ 0.5 μ g/mL)	77 (68%)	11 (38%)	65 (78%)

Table S6. The eigenvalue and proportion of variance of PC. Related to Figure 2.

PC summary	Eigenvalue	Proportion of variance
PC1	4.297	39.06%
PC2	1.31	11.91%
PC3	1.205	10.96%
PC4	0.8182	7.44%
PC5	0.7663	6.97%
PC6	0.6775	6.16%
PC7	0.5896	5.36%
PC8	0.4413	4.01%
PC9	0.3843	3.49%
PC10	0.2636	2.40%
PC11	0.2475	2.25%

Table S7. Two linear components identified by PCA analysis. Related to Figure 2.

Variable	PC coordinates	
	PC1	PC2
Age	0.366544108	-0.372529379
LDH	0.780416637	0.252252406
D-dimer	0.621952849	-0.020073195
Platelet	-0.5235183	0.517697281
Lymphocyte	-0.6832239	0.259927509
Neutrophil	0.71501817	0.274990703
IFP35	0.284744614	0.686997811
IL-6	0.769585878	-0.080777968
TNF	0.508479132	0.418633499
PCT	0.509028314	-0.198843574
CRP	0.850426181	-0.048143317




Figure S1. The secretion of IFP35 in RAW264.7 cells and C57BL/6J mice infected by influenza virus. Related to Figure 4. (A) 6×10^6 RAW264.7 cells were seeded into 6-well plate 12 hours prior to influenza virus infection (5MOI PR8). The supernatant of the cells was collected at 0 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h and 24 h post-infection. The experiment was repeated for 3 times. (B-D) 6-8 week old male C57BL/6J mice were randomly divided into 6 groups (n=5 in each group) and infected with 2LD₅₀ PR8 virus. After that, each group of mice were bled and isolated for serum at 0 day, 1 day, 2 days, 3 days, 5 days and 7 days post-infection. The serum mIFP35 was detected by ELISA (B). Characteristic lung tissues of the mice staining with hematoxylin and eosin, the scale bar is 100 μ m (C). The pathological score of all the lung tissues of the mice was shown in (D). Data in (A), (B) and (D) are mean values \pm SEM. Significance in (A) was calculated with the unpaired student's t test. Significance in (B) and (D) was assessed by Mann-Whitney U test. (*P < 0.05, **P < 0.01, ***P < 0.001)